Abstract
Hypercoagulability and virally-mediated vascular inflammation have become well-recognized features of the SARS-CoV-2 virus infection, COVID-19. Of growing concern is the apparent ineffectiveness of therapeutic anticoagulation in preventing thromboembolic events among some at-risk patient subtypes with COVID-19. We present a 43-year-old female with a history of seropositive-antiphospholipid syndrome and systemic lupus erythematosus who developed an acute ischemic stroke in the setting of mild COVID-19 infection despite adherence to chronic systemic anticoagulation. The clinical significance of SARS-CoV-2-mediated endothelial cell dysfunction and its potential to cause macrovascular events in spite of full anticoagulation warrants further investigation and likely represents another disease-defining pathology of COVID-19.
Keywords: Anti-phospholipid; Anticoagulation; COVID-19; Hypercoagulable state; ischemic stroke.
【저자키워드】 COVID-19, anticoagulation, Anti-phospholipid, Hypercoagulable state, ischemic stroke., 【초록키워드】 pathology, anticoagulation, stroke, Infection, SARS-CoV-2 virus, systemic lupus erythematosus, COVID-19 infection, Ischemic Stroke, female, Patient, Clinical significance, Mild, virus infection, hypercoagulability, Hypercoagulable state, Endothelial cell, therapeutic anticoagulation, lupus erythematosus, hypercoagulable, dysfunction, thromboembolic, Thromboembolic events, syndrome, SARS-CoV-2 virus infection, systemic anticoagulation, vascular inflammation, phospholipid, subtype, Thromboembolic event, feature, event, the SARS-CoV-2 virus, with COVID-19, 【제목키워드】 failure, Context,